Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance profiles

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 340-348

  Gilbert, Peter ^a   Degruttola, Victor ^b   Hammer, Scott ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; INDINAVIR; NELFINAVIR; PLACEBO; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; DRUG EFFICACY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RETROVIRUS; VIRUS RESISTANCE;

EID: 0031850584     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515647     Document Type: Article

References (22)

1. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996;10(suppl)3:S1-11.
2. Mathez D, De Truchis P, Gorin I, et al. Ritonavir, AZT, ddC, as a triple combination in AIDS patients (abstract 258). In: 3rd Conference on Human Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996.
3. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
4. Markowitz M, Cao Y, Vesanen M, et al. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor (abstract). In 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997.
5. ISIS-4 Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
6. Ho D. Time to hit HIV, early and hard. N Engl J Med 1995;333:450-1.
7. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA Panel. JAMA 1997;277:1962-9.
8. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:144-53.
9. Staszewski S. Zidovudine and lamivudine: results of phase III studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(suppl 1):S57.
10. Schoenfeld DA. AIDS clinical trials. Chapter 17. New York: John Wiley & Sons, 1995.
11. Byar DP, Piantadosi S. Factorial designs for randomized clinical trials. Cancer Treat Rep 1985;69:1055-63.
12. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
13. Wu H, Ding AA, DeGruttola V. Estimation of HIV dynamic parameters. Stat Med 1998 (in press).
14. Stampfer MJ, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH. The 2 × 2 factorial design: its applications to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 1985;4:111-6.
15. Ellenberg SS, Finkelstein DM, Schoenfeld DA. Statistical issues arising in AIDS clinical trials. J Am Stat Assoc 1992;87:562-9.
16. Box GEP, Hunter WG, Hunter, JS. Statistics for experimenters. New York: John Wiley & Sons, 1978.
17. Neter J, Wasserman W, Kutner MH. Applied linear statistical models. 3rd ed. Chapters 18, 22. Homewood, IL: Irwin, 1990.
18. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
19. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
20. Searle SR. Linear models for unbalanced data. Chapter 5. New York: John Wiley & Sons, 1987.
21. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
22. Slud EV. Analysis of factorial survival experiments. Biometrics 1994;50:25-38.